This page will appear automatically.
A GHRH analogue for growth-hormone-axis research.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It is studied in defined clinical contexts for its effect on growth-hormone signalling, IGF-1 and body composition, particularly visceral-fat outcomes.
Tesamorelin stimulates pituitary GHRH receptors, increasing pulsatile growth-hormone release and downstream IGF-1 signalling. This pathway affects multiple tissues and requires careful monitoring.
Tesamorelin has human evidence in a specific medical context. That evidence does not transfer automatically to general weight management, performance, anti-ageing use or a different presentation.
Changes in visceral fat or biomarkers do not establish broader health benefit. Product equivalence, long-term use and outcomes outside authorised populations are not established.
May affect glucose regulation, fluid balance and growth-factor pathways. Active malignancy, pituitary conditions, pregnancy and other contraindications require qualified clinical assessment.
Published or handbook ranges do not establish individual suitability or directions.
Health conditions, medicines, allergies and monitoring needs require individual consideration.
Storage: Store refrigerated at 2 to 8°C, protected from light. Do not freeze. Follow the batch-specific label and handling information supplied with the product.
No. Reference amounts describe source-reported research context only, not a personal recommendation.
Grade A describes how much information is available, not whether Tesamorelin is right for you. See the evidence section above for detail.
Ordering is not currently available through this site. Enquire and our team will advise on availability in your market.
Contact our support team with the product name and batch reference and we'll help directly.
